Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
Phase 3
Active, not recruiting
- Conditions
- Phosphomannomutase 2 DeficiencyPhosphomannomutase 2 Congenital Disorder of GlycosylationPhosphomannomutase II Congenital Disorder of GlycosylationPhosphomannomutase II DeficiencyPmm2-CDG
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Maggie's Pearl, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT04925960
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath